Gamco Investors INC. ET AL increased its stake in Amgen, Inc. (NASDAQ:AMGN) by 20.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 7,286 shares of the medical research company’s stock after purchasing an additional 1,242 shares during the period. Gamco Investors INC. ET AL’s holdings in Amgen were worth $1,410,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also bought and sold shares of the company. BlackRock Inc. boosted its stake in shares of Amgen by 3.4% during the 2nd quarter. BlackRock Inc. now owns 47,717,316 shares of the medical research company’s stock worth $8,793,346,000 after buying an additional 1,585,911 shares during the last quarter. Morgan Stanley boosted its stake in shares of Amgen by 0.5% during the 2nd quarter. Morgan Stanley now owns 6,753,145 shares of the medical research company’s stock worth $1,244,470,000 after buying an additional 34,674 shares during the last quarter. Nuveen Asset Management LLC boosted its stake in shares of Amgen by 1,334.9% during the 2nd quarter. Nuveen Asset Management LLC now owns 4,942,807 shares of the medical research company’s stock worth $910,860,000 after buying an additional 4,598,329 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Amgen by 9.4% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 2,780,461 shares of the medical research company’s stock valued at $512,383,000 after purchasing an additional 239,576 shares during the period. Finally, Putnam Investments LLC raised its holdings in shares of Amgen by 8.9% in the 2nd quarter. Putnam Investments LLC now owns 1,851,073 shares of the medical research company’s stock valued at $341,116,000 after purchasing an additional 151,910 shares during the period. Institutional investors own 76.33% of the company’s stock.
In related news, SVP Cynthia M. Patton sold 13,426 shares of Amgen stock in a transaction on Friday, August 30th. The shares were sold at an average price of $208.07, for a total transaction of $2,793,547.82. Following the completion of the transaction, the senior vice president now owns 32,648 shares of the company’s stock, valued at $6,793,069.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director R Sanders Williams sold 425 shares of Amgen stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $215.45, for a total transaction of $91,566.25. Following the transaction, the director now directly owns 5,413 shares of the company’s stock, valued at approximately $1,166,230.85. The disclosure for this sale can be found here. In the last quarter, insiders have sold 17,851 shares of company stock worth $3,685,674. 0.25% of the stock is owned by company insiders.
Shares of AMGN traded up $3.12 during mid-day trading on Friday, hitting $221.11. 2,069,900 shares of the company’s stock were exchanged, compared to its average volume of 2,911,719. Amgen, Inc. has a 52 week low of $166.30 and a 52 week high of $221.25. The company has a quick ratio of 2.59, a current ratio of 2.89 and a debt-to-equity ratio of 2.54. The firm has a market cap of $127.80 billion, a price-to-earnings ratio of 15.35, a price-to-earnings-growth ratio of 2.21 and a beta of 1.09. The stock’s 50-day simple moving average is $202.75 and its 200-day simple moving average is $188.90.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, October 29th. The medical research company reported $3.66 EPS for the quarter, topping analysts’ consensus estimates of $3.53 by $0.13. The company had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.63 billion. Amgen had a net margin of 34.48% and a return on equity of 80.26%. Amgen’s revenue was down 2.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.69 earnings per share. Analysts forecast that Amgen, Inc. will post 14.44 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, December 6th. Stockholders of record on Friday, November 15th will be issued a dividend of $1.45 per share. The ex-dividend date is Thursday, November 14th. This represents a $5.80 dividend on an annualized basis and a dividend yield of 2.62%. Amgen’s dividend payout ratio (DPR) is presently 40.28%.
A number of equities research analysts have recently issued reports on AMGN shares. JPMorgan Chase & Co. reaffirmed a “hold” rating on shares of Amgen in a report on Monday, September 30th. Citigroup reaffirmed a “buy” rating on shares of Amgen in a report on Monday, August 12th. Leerink Swann increased their price target on shares of Amgen from $189.00 to $205.00 and gave the company a “market perform” rating in a report on Wednesday, October 30th. Morgan Stanley lowered their price target on shares of Amgen from $211.00 to $207.00 and set an “overweight” rating on the stock in a report on Monday, July 15th. Finally, Oppenheimer set a $240.00 price target on shares of Amgen and gave the company a “buy” rating in a report on Monday, September 9th. Ten analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $219.56.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Recommended Story: Dow Jones Industrial Average (DJIA)
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.